NTRA

Natera Inc
$311.26-$9.13-2.85%Price as of Nov 10, 2026, 5:50 PM ET

Key stats

Market cap
44.9B
Open
—
Day range
—
52-week range
$181.00 – $437.41
Volume
1.74M
Avg volume
1.98M

Earnings

Q3 FY26Miss
Expected$-0.30
Actual$-0.42
Q2 FY26
Actual$-0.47
Q1 FY26
Actual$-0.60
Q4 FY25
Actual$0.34

Next earnings call Feb 26, 2027

About

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Employees
6,140
Headquarters
Austin, TX